Meeting
2020 ASCO Virtual Scientific Program
Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III locally advanced non-small cell lung cancer patients.
Authors
Yoshitaka Zenke
National Cancer Center Hospital East, Kashiwa, Japan
Yoshitaka Zenke , Shingo Matsumoto , Terufumi Kato , Shingo Miyamoto , Takuma Imakita , Tetsuya Mitsudomi , Hiromi Aono , Ryota Ushio , Naoki Furuya , Kazumi Nishino , Saori Takata , Mika Nakao , Satoshi Hara , Motoko Tachihara , Akimasa Sekine , Jun Sakakibara-Konishi , Ryo Toyozawa , Kiyotaka Yoh , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9038)
DOI
10.1200/JCO.2020.38.15_suppl.9038
Abstract #
9038
Poster Bd #
231
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
First Author: Benjamin J. Solomon
Poster
2023 ASCO Annual Meeting
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
First Author: Benjamin Herzberg
Poster
2021 ASCO Annual Meeting
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
First Author: Shingo Matsumoto
Poster
2020 ASCO Virtual Scientific Program
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.
First Author: Shingo Matsumoto